Baypoint Bio Licenses Ovarian, Breast Cancer Dx IP from MD Anderson

Mar 27, 2008

NEW YORK (GenomeWeb News) – Baypoint Biosystems said today it has licensed predictive biomarker intellectual property from the University of Texas MD Anderson Cancer Center in Houston.

The privately held company has obtained exclusive, worldwide rights to commercialize certain proteomics IP and clinical biomarkers for predicting therapeutic responses for certain ovarian and breast cancers.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

From Relatives to Suspects

Parabon NanoLabs is partnering with law enforcement to use genetic genealogy approaches to solve cold cases, Buzzfeed News reports.

Family Ties

A Columbia University-led team used emergency contact information from medical records to create family trees and estimate disease heritability.

This Week in Science

In Science this week: ancient Southeast Asian genomes provide insight on human migration, and more.

Time to Kick Back With Some Golf

NPR says a new report recommends that former research chimpanzees should be moved to retirement sanctuaries unless that move would shorten their lives.

Main menu